Product

Preclinical

Ph1

Ph2

Ph3

Unmodified INTELLIGENT invariant Natural Killer T Cells (iNKT Cells)
AGENT-797
Mechanism/Target:
Hematological Malignancies
Anticipated Milestones:
Phase 1 Readout in Q4 ‘21
AGENT-797
Mechanism/Target:
COVID-19 Related Pneumonia
Anticipated Milestones:
Phase 1 Readout in Q4 ‘21
AGENT-797 +
PD-1/CTLA-4
Mechanism/Target:
NSCLC, SCCHN, HCC
Anticipated Milestones:
IND Filing H1 ‘21
Targeted INTELLIGENT iNKT Cells
Mechanism/Target:
Multiple Undisclosed CARs - Solid Tumors
Mechanism/Target:
Undisclosed Bispecific iNKT Cell Engager
Mechanism/Target:
PTT TCRs
Mechanism/Target Product Preclinical Ph1 Ph2 Ph3 Anticipated Milestones
Unmodified INTELLIGENT invariant Natural Killer T Cells (iNKT Cells)
Hematological MalignanciesAGENT-797Phase 1 Readout in Q4 ‘21
COVID-19 Related PneumoniaAGENT-797Phase 1 Readout in Q4 ‘21
NSCLC, SCCHN, HCCAGENT-797 +
PD-1/CTLA-4
IND Filing H1 ‘21
Targeted INTELLIGENT iNKT Cells
Multiple Undisclosed CARs - Solid Tumors
Undisclosed Bispecific iNKT Cell Engager
PTT TCRs